Inorganic phosphate and FGF-23 predict outcome in stable systolic heart failure

European Journal of Clinical Investigation

Volumn 42, Issue 6, 2012, Pages 649-656

  Plischke, Max ^a   Neuhold, Stephanie ^a   Adlbrecht, Christopher ^a   Bielesz, Bernhard ^a   Shayganfar, Sascha ^a   Bieglmayer, Christian ^a   Szekeres, Thomas ^a   Hörl, Walter H ^a   Strunk, Guido ^b   Vavken, Patrick ^c,d   Pacher, Richard ^a   Hülsmann, Martin ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b VIENNA UNIVERSITY OF ECONOMICS AND BUSINESS   (Austria)

^c BOSTON CHILDREN S HOSPITAL   (United States)

^d HARVARD CENTER FOR POPULATION AND DEVELOPMENT STUDIES   (United States)

Author keywords

FGF 23; Heart failure; Mortality; Phosphates; Rehospitalization

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR 23; PHOSPHATE;

ADULT; ARTICLE; CLINICAL ASSESSMENT TOOL; CORRELATION ANALYSIS; CREATININE CLEARANCE; FEMALE; FOLLOW UP; HAZARD RATIO; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW YORK HEART ASSOCIATION; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; SYSTOLIC HEART FAILURE;

COHORT STUDIES; FEMALE; FIBROBLAST GROWTH FACTORS; HEART FAILURE, SYSTOLIC; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PHOSPHATES; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSPECTIVE STUDIES; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 84860921021     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02631.x     Document Type: Article

References (41)

1. Sugimoto T, Tanigawa T, Onishi K, Fujimoto N, Matsuda A, Nakamori S et al. Serum intact parathyroid hormone levels predict hospitalisation for heart failure. Heart 2009;95:395-8.
2. Schierbeck LL, Jensen TS, Bang U, Jensen G, Kober L, Jensen JE. Parathyroid hormone and vitamin D - markers for cardiovascular and all cause mortality in heart failure. Eur J Heart Fail 2011;13:626-32.
3. Shane E, Mancini D, Aaronson K, Silverberg SJ, Seibel MJ, Addesso V et al. Bone mass, vitamin D deficiency, and hyperparathyroidism in congestive heart failure. Am J Med 1997;103:197-207.
4. Zittermann A, Schleithoff SS, Tenderich G, Berthold HK, Korfer R, Stehle P. Low vitamin D status: a contributing factor in the pathogenesis of congestive heart failure? J Am Coll Cardiol 2003;41:105-12.
5. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-17.
6. Ganesh SK, Stack AG, Levin NW, Hulbert-Shearon T, Port FK. Association of elevated serum PO(4), Ca x PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-8.
7. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-18.
8. Larsson TE, Olauson H, Hagstrom E, Ingelsson E, Arnlov J, Lind L et al. Conjoint effects of serum calcium and phosphate on risk of total, cardiovascular, and noncardiovascular mortality in the community. Arterioscler Thromb Vasc Biol 2009;30:333-9.
9. Dhingra R, Sullivan LM, Fox CS, Wang TJ, D'Agostino RB Sr, Gaziano JM et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch Intern Med 2007;167:879-85.
10. Tonelli M, Sacks F, Pfeffer M, Gao Z, Curhan G. Relation between serum phosphate level and cardiovascular event rate in people with coronary disease. Circulation 2005;112:2627-33.
11. Dhingra R, Gona P, Benjamin EJ, Wang TJ, Aragam J, D'Agostino RB Sr et al. Relations of serum phosphorus levels to echocardiographic left ventricular mass and incidence of heart failure in the community. Eur J Heart Fail 2010;12:812-8.
12. Larsson TE. The role of FGF-23 in CKD-MBD and cardiovascular disease: friend or foe? Nephrol Dial Transplant 2010;25:1376-81.
13. Hruska KA, Choi ET, Memon I, Davis TK, Mathew S. Cardiovascular risk in chronic kidney disease (CKD): the CKD-mineral bone disorder (CKD-MBD). Pediatr Nephrol 2010;25:769-78.
14. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-9.
15. Gutierrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-92.
16. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007;18:2600-8.
17. Seiler S, Reichart B, Roth D, Seibert E, Fliser D, Heine GH. FGF-23 and future cardiovascular events in patients with chronic kidney disease before initiation of dialysis treatment. Nephrol Dial Transplant 2010;25:3983-9.
18. Jean G, Terrat JC, Vanel T, Hurot JM, Lorriaux C, Mayor B et al. High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant 2009;24:2792-6.
19. Parker BD, Schurgers LJ, Brandenburg VM, Christenson RH, Vermeer C, Ketteler M et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010;152:640-8.
20. Adlbrecht C, Kommata S, Hulsmann M, Szekeres T, Bieglmayer C, Strunk G et al. Chronic heart failure leads to an expanded plasma volume and pseudoanaemia, but does not lead to a reduction in the body's red cell volume. Eur Heart J 2008;29:2343-50.
21. Lambers Heerspink HJ, Brantsma AH, de Zeeuw D, Bakker SJ, de Jong PE, Gansevoort RT. Albuminuria assessed from first-morning-void urine samples versus 24-hour urine collections as a predictor of cardiovascular morbidity and mortality. Am J Epidemiol 2008;168:897-905.
22. Alsafwah S, Laguardia SP, Nelson MD, Battin DL, Newman KP, Carbone LD et al. Hypovitaminosis D in African Americans residing in Memphis, Tennessee with and without heart failure. Am J Med Sci 2008;335:292-7.
23. Pilz S, Marz W, Wellnitz B, Seelhorst U, Fahrleitner-Pammer A, Dimai HP et al. Association of vitamin D deficiency with heart failure and sudden cardiac death in a large cross-sectional study of patients referred for coronary angiography. J Clin Endocrinol Metab 2008;93:3927-35.
24. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-81.
25. Witham MD, Crighton LJ, Gillespie ND, Struthers AD, McMurdo ME. The effects of vitamin D supplementation on physical function and quality of life in older patients with heart failure: a randomized controlled trial. Circ Heart Fail 2010;3:195-201.
26. Laguardia SP, Dockery BK, Bhattacharya SK, Nelson MD, Carbone LD, Weber KT. Secondary hyperparathyroidism and hypovitaminosis D in African-Americans with decompensated heart failure. Am J Med Sci 2006;332:112-8.
27. Arroyo M, Laguardia SP, Bhattacharya SK, Nelson MD, Johnson PL, Carbone LD et al. Micronutrients in African-Americans with decompensated and compensated heart failure. Transl Res 2006;148:301-8.
28. Grandi NC, Breitling LP, Hahmann H, Wusten B, Marz W, Rothenbacher D et al. Serum parathyroid hormone and risk of adverse outcomes in patients with stable coronary heart disease. Heart 2011;97:1215-21.
29. Zittermann A, Schleithoff SS, Gotting C, Dronow O, Fuchs U, Kuhn J et al. Poor outcome in end-stage heart failure patients with low circulating calcitriol levels. Eur J Heart Fail 2008;10:321-7.
30. Kawata T, Imanishi Y, Kobayashi K, Miki T, Arnold A, Inaba M et al. Parathyroid hormone regulates fibroblast growth factor-23 in a mouse model of primary hyperparathyroidism. J Am Soc Nephrol 2007;18:2683-8.
31. Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB et al. Fibroblast growth factor-23 regulates parathyroid hormone and 1alpha-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 2007;195:125-31.
32. Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M et al. The parathyroid is a target organ for FGF23 in rats. J Clin Invest 2007;117:4003-8.
33. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009;207:546-51.
34. Wu F, Zhang EY, Zhang J, Bache RJ, Beard DA. Phosphate metabolite concentrations and ATP hydrolysis potential in normal and ischaemic hearts. J Physiol 2008;586:4193-208.
35. He MX, Wang S, Downey HF. Correlation between myocardial contractile force and cytosolic inorganic phosphate during early ischemia. Am J Physiol 1997;272:H1333-41.
36. Allen DG, Lamb GD, Westerblad H. Impaired calcium release during fatigue. J Appl Physiol 2008;104:296-305.
37. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res 2006;98:905-12.
38. Carson P, Tam SW, Ghali JK, Archambault WT, Taylor A, Cohn JN et al. Relationship of quality of life scores with baseline characteristics and outcomes in the African-American heart failure trial. J Card Fail 2009;15:835-42.
39. Heidenreich PA, Spertus JA, Jones PG, Weintraub WS, Rumsfeld JS, Rathore SS et al. Health status identifies heart failure outpatients at risk for hospitalization or death. J Am Coll Cardiol 2006;47:752-6.
40. Iqbal J, Francis L, Reid J, Murray S, Denvir M. Quality of life in patients with chronic heart failure and their carers: a 3-year follow-up study assessing hospitalization and mortality. Eur J Heart Fail 2010;12:1002-8.
41. Hulsmann M, Berger R, Sturm B, Bojic A, Woloszczuk W, Bergler-Klein J et al. Prediction of outcome by neurohumoral activation, the six-minute walk test and the Minnesota Living with Heart Failure Questionnaire in an outpatient cohort with congestive heart failure. Eur Heart J 2002;23:886-91.